Protalix BioTherapeutics, Inc. (PLX) AI Stock Analysis

Protalix BioTherapeutics, Inc. is a biopharmaceutical firm that develops recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system. The company operates globally across the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. It is known for Elelyso, an approved treatment for Gaucher disease. Its clinical development pipeline includes PRX-102 for Fabry disease, PRX-110 for cystic fibrosis, PRX-115 for gout, and PRX-119 targeting conditions related to neutrophil extracellular traps. Protalix maintains collaborations with major pharmaceutical partners, including Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A.

Protalix experienced variable revenue over recent periods, resulting in a 5-year revenue CAGR of -3.5% from FY2020 to FY2025. After peaking at $65.5M in FY2023 with net income of $8.3M, revenue dropped 18.5% in FY2024 to $53.4M and fell 1.2% in FY2025 to $52.7M. Operating margin moved from 16.0% in FY2023 to -10.4% in FY2025, when the company recorded a net loss of -$6.6M. Results rebounded in the trailing twelve months ended June 30, 2026, reaching $80.6M in revenue, supported by latest quarter revenue growth of 27.1% and quarterly earnings growth of 2241.1%.

As of June 30, 2026, Protalix held $40.7M in cash and short-term investments against total debt of $9.2M, leaving net cash of $31.4M. Its liquidity profile shows a current ratio of 2.94 and a debt-to-equity ratio of 0.13 relative to $71.4M in shareholders' equity. In FY2025, operating cash flow was -$12.0M and free cash flow was -$13.6M, with capital expenditures totaling $1.6M. Cash generation was supported by $9.3M in share issuance during FY2025, contributing to an 81.2% increase in share count over 5 years.

At a share price of $2.62, Protalix carries a market cap of $211.1M and an enterprise value of $194.2M. The stock trades at a trailing P/E of 11.4x, well below the 24.6x median of its US-listed Healthcare peers, but its forward P/E of 55.9x trades at a premium to the peer median of 17.3x. Its price-to-sales multiple is 2.6x versus the peer median of 4.1x, and its EV/EBITDA stands at 7.4x against the peer median of 12.0x. Over the past year, the stock returned 9.2%, trailing the S&P 500 return of 16.8%, but its 5-year return of 113.0% outperformed the S&P 500 return of 83.0%.

Protalix currently has 1 Buy rating and zero Hold or Sell ratings from covering analysts. The mean price target is $11.00, representing an implied upside of 319.8% above the last closing price of $2.62. For the fiscal year ending December 31, 2026, analysts estimate revenue of $82.2M and EPS of $0.24, reflecting projected EPS growth of 400.0%. However, 2 analysts expect FY2027 revenue to decline 19.1% to $66.5M with EPS dropping 79.2% to $0.05. The company beat EPS estimates in 2 of the past 4 quarters, with next earnings scheduled for November 12, 2026.

This page is an AI-written research summary of Protalix BioTherapeutics, Inc. (PLX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PLX income statement, PLX balance sheet, PLX key metrics, PLX analyst forecast, PLX chart. See the PLX stock overview for the latest quote and news.